Penumbra (NYSE:PEN) Cut to Hold at Needham & Company LLC

Needham & Company LLC lowered shares of Penumbra (NYSE:PEN) from a buy rating to a hold rating in a research report report published on Friday morning, Marketbeat.com reports.

PEN has been the topic of several other reports. Weiss Ratings reissued a “hold (c)” rating on shares of Penumbra in a report on Monday, December 29th. William Blair downgraded Penumbra from an “outperform” rating to a “market perform” rating in a report on Thursday. Piper Sandler lowered Penumbra from an “overweight” rating to a “hold” rating and set a $374.00 price target for the company. in a research report on Thursday. Leerink Partners cut Penumbra to a “market perform” rating in a research note on Friday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $355.00 price objective on shares of Penumbra in a research report on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $355.88.

Penumbra Stock Performance

Shares of Penumbra stock opened at $350.93 on Friday. The company has a current ratio of 6.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock’s fifty day moving average price is $303.54 and its 200-day moving average price is $269.79. The firm has a market cap of $13.74 billion, a P/E ratio of 83.95, a P/E/G ratio of 2.14 and a beta of 0.71. Penumbra has a 12 month low of $221.26 and a 12 month high of $352.15.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.85 EPS. On average, equities research analysts expect that Penumbra will post 3.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arani Bose sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $308.82, for a total transaction of $4,632,300.00. Following the transaction, the director owned 258,462 shares in the company, valued at $79,818,234.84. This represents a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Harpreet Grewal sold 186 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $227.58, for a total transaction of $42,329.88. Following the completion of the transaction, the director directly owned 8,516 shares of the company’s stock, valued at $1,938,071.28. The trade was a 2.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 34,144 shares of company stock valued at $10,260,127 in the last 90 days. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Penumbra

Several large investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its holdings in shares of Penumbra by 35.8% in the first quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock worth $5,169,000 after buying an additional 5,092 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Penumbra by 53.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,999 shares of the company’s stock valued at $1,255,000 after buying an additional 1,748 shares during the last quarter. Diversified Trust Co increased its position in shares of Penumbra by 33.3% in the 2nd quarter. Diversified Trust Co now owns 8,365 shares of the company’s stock valued at $2,147,000 after acquiring an additional 2,089 shares during the period. Farther Finance Advisors LLC raised its stake in Penumbra by 408.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,262 shares of the company’s stock worth $580,000 after acquiring an additional 1,817 shares during the last quarter. Finally, Park Avenue Securities LLC purchased a new position in Penumbra in the 2nd quarter worth $408,000. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra News Roundup

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.